Haleon plc (LON:HLN) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Haleon has an average “Hold” rating among six analysts: three recommend buying, two recommend selling and one recommends holding. The average 12-month price target is GBX 395.67.
• Recent analyst views remain mixed, with price targets ranging from GBX 315 to GBX 514. Jefferies and Berenberg remain bullish, while Deutsche Bank and JPMorgan maintain bearish ratings.
• Haleon shares opened at GBX 367, down 0.6%, while the company recently reported quarterly earnings of GBX 8.60 per share, a 15.11% net margin and a 10.30% return on equity.

Haleon plc (LON:HLN - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is GBX 395.67.

HLN has been the subject of several recent research reports. Jefferies Financial Group reissued a "buy" rating and issued a GBX 400 price target on shares of Haleon in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lifted their target price on Haleon from GBX 325 to GBX 335 and gave the company a "sell" rating in a research note on Friday, July 31st. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a GBX 370 price objective on shares of Haleon in a research report on Thursday, April 30th. JPMorgan Chase & Co. reduced their price objective on shares of Haleon from GBX 335 to GBX 315 and set an "underweight" rating for the company in a research note on Thursday, June 25th. Finally, Berenberg Bank raised their price target on Haleon from GBX 512 to GBX 514 and gave the stock a "buy" rating in a report on Wednesday, August 5th.

Haleon Trading Down 0.6%

LON HLN opened at GBX 367 on Monday. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92. The company has a market capitalization of £32.32 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company's 50-day simple moving average is GBX 352.14 and its two-hundred day simple moving average is GBX 363.16.

Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 15.11% and a return on equity of 10.30%. Equities analysts forecast that Haleon will post 19.5033282 EPS for the current fiscal year.

Haleon Company Profile

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source